Antares Pharma Announces Positive Results From Its Pivotal Phase 3 Study Of Anturol Gel For The Treatment Of Overactive Bladder
Antares Pharma, Inc. has announced positive results from its Phase 3 study of AnturolTM Gel in patients with overactive bladder (OAB). The study met its primary endpoint of a statistically significant reduction in urinary incontinence episodes for both doses studied (56 mg daily or 84 mg daily, p=0.028 and 0.033 respectively). An Open Label Extension study, evaluating long term safety remains ongoing and is scheduled to complete by Q4 2010.
Read the full story here

